Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
Somnath Chakraborty, Jay Sheth
Abstract
The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.
Topics & Concepts
Diabetic macular edemaMedicineOphthalmologyVisual acuityMacular edemaDiabetic retinopathyDiabetes mellitusEndocrinologyRetinal Diseases and TreatmentsAdenosine and Purinergic SignalingComplement system in diseases